Infiltration of CD8+ lymphocytes is an independent prognostic factor of biochemical failure-free survival in prostate cancer: CD8+ Lymphocytes in Prostate Cancer
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
BACKGROUNDS: The adaptive immune system can potentially have dual roles in cancer development and progression by contributing to or suppressing tumor progression and metastasis. The aim of this study was to evaluate the prognostic impact of adaptive immune cells residing in different tumor compartments in prostate cancer. METHODS: Tissue microarrays from 535 patients were constructed from viable and representative tumor epithelial and stromal areas of primary PC tumors, as well as from normal epithelial and stromal areas. Immunohistochemistry was used to evaluate the density of CD3+, CD4+, CD8+, and CD20+ lymphocytes in both tumor epithelial and tumor stromal areas. RESULTS: In univariate analysis, a high density of CD3+ (P = 0.037) and CD8+ lymphocytes (P = 0.010) in tumor epithelial areas was associated with significantly shorter biochemical failure-free survival. When analyzing both tumor epithelial and stromal tissue compartments as one entity, similar relationships were observed for CD3+ (P = 0.046), CD4+ (P = 0.026), and CD8+ (P = 0.003) lymphocytes. In multivariate analysis, high densities of CD8+ lymphocytes limited to tumor epithelial areas (HR = 1.45, P = 0.032), as well as in the total tumor tissue (HR = 1.57, P = 0.007), were independent negative prognostic factors for biochemical failure-free survival. CONCLUSIONS: A high density of CD8+ lymphocytes, especially in tumor epithelial areas, is an independent negative prognostic factor for biochemical failure-free survival.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The immune contexture in human tumours: impact on clinical outcome
Fridman, W. H., Pagès, F., Sautès-Fridman, C., & Galon, J. (2012) · Nature reviews. Cancer · doi:10.1038/nrc3245 · Cited by 4,981 · cited 1×
“In colorectal cancer, immune scores (IS) [9] appear to be a better prognostic indicator than the TNM system [10], and may be applicable in other cancer types as well.”
Mlecnik, B., Tosolini, M., Kirilovsky, A., Berger, A., Bindea, G., Meatchi, T., Bruneval, P., Trajanoski, Z., Fridman, W.-H., Pagès, F., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.5425 · Cited by 1,009
Cited by
Immunological effects of conventional chemotherapy and targeted anticancer agents
Galluzzi, L., Buqué, A., Kepp, O., Zitvogel, L., & Kroemer, G. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.10.012 · Cited by 1,530
Hendry, S., Salgado, R., Gevaert, T., Russell, P. A., John, T., Thapa, B., Christie, M., van de Vijver, K., Estrada, M. V., Gonzalez-Ericsson, P. I., et al. (2017) · Advances in Anatomic Pathology · doi:10.1097/pap.0000000000000161 · Cited by 799
Prognostic Significance of Tumor-Infiltrating B Cells and Plasma Cells in Human Cancer
Wouters, M. C. A., & Nelson, B. H. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1481 · Cited by 495
Immunogenic effects of chemotherapy-induced tumor cell death
Wang, Y.-J., Fletcher, R., Yu, J., & Zhang, L. (2018) · Genes & Diseases · doi:10.1016/j.gendis.2018.05.003 · Cited by 314
The untold story of IFN-γ in cancer biology
Kursunel, M. A., & Esendagli, G. (2016) · Cytokine & Growth Factor Reviews · doi:10.1016/j.cytogfr.2016.07.005 · Cited by 192
Metadata
- Authors
- Ness, N., Andersen, S., Valkov, A., Nordby, Y., Donnem, T., Al-Saad, S., Busund, L.-T., Bremnes, R. M., & Richardsen, E.
- Venue
- The Prostate
- Publisher
- Wiley
- Published
- 2014-08-11
- Volume
- 74
- Issue
- 14
- Pages
- 1452-1461
- ISSN
- 0270-4137 (ISSN-L)
- OpenAlex
- W1500124513
- Cited by
- 114
- References
- 2
- FWCI
- 5.09
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.